阅读说明：本技术 具备经由futalosine或futalosine衍生物的甲基萘醌合成途径的细菌的增殖抑制用组合物 (Composition for inhibiting proliferation of bacteria having menaquinone synthesis pathway via futalosine or futalosine derivative ) 是由 松井英则 川口真里奈 于 2018-02-23 设计创作，主要内容包括：本发明提供：具备经由futalosine或futalosine衍生物的甲基萘醌合成途径的细菌的增殖抑制用组合物,该组合物含有10位上具有羟基的碳原子数为18的脂肪酸作为有效成分；以及由具备经由futalosine或futalosine衍生物的甲基萘醌合成途径的细菌引起的疾病的预防或治疗用组合物。(The present invention provides: a composition for inhibiting the growth of a bacterium having a menaquinone synthesis pathway via futalosine or a futalosine derivative, the composition containing a fatty acid having a hydroxyl group at the 10-position and having 18 carbon atoms as an active ingredient; and a composition for preventing or treating a disease caused by a bacterium having a menaquinone synthesis pathway via futalosine or a futalosine derivative.)

1. A composition for inhibiting the growth of a bacterium having a menaquinone synthesis pathway via futalosine or a futalosine derivative, said composition comprising a fatty acid having a hydroxyl group at the 10-position and having 18 carbon atoms.

2. The composition of claim 1, wherein the fatty acid has a cis double bond at least at position 12.

3. The composition as set forth in claim 2, wherein the fatty acid is at least one selected from the group consisting of 10-hydroxy-cis-12-octadecenoic acid, 10-hydroxy-cis-12, cis-15-octadecadienoic acid and 10-hydroxy-cis-6, cis-12-octadecadienoic acid.

4. The composition of claim 3, wherein the fatty acid is 10-hydroxy-cis-12-octadecenoic acid.

5. A composition as claimed in any one of claims 1 to 4, wherein the bacteria are helicobacter bacteria.

6. the composition of claim 5, wherein the helicobacter is selected from the group consisting of helicobacter pylori, helicobacter suis.

7. The composition of claim 5 or 6, which is used for the prevention or treatment of a disease selected from the group consisting of acute gastritis, chronic gastritis, nodular gastritis, gastric ulcer, duodenal ulcer, gastric cancer, gastric MALT lymphoma, diffuse large B-cell lymphoma, idiopathic thrombocytopenic purpura, infantile iron-deficiency anemia, chronic urticaria and parkinson's disease.

8. The composition according to any one of claims 1 to 4, wherein the bacterium is a Campylobacter bacterium.

9. The composition of claim 8, wherein the bacteria of the genus campylobacter are selected from campylobacter jejuni, campylobacter coli.

10. The composition of claim 8 or 9 for use in the prevention or treatment of campylobacter food poisoning or guillain-barre syndrome.

11. The composition according to any one of claims 1 to 10, which is a food or food additive.

12. The composition according to any one of claims 1 to 10, which is a pharmaceutical product.

13. The composition of any one of claims 1 to 10, which is a feed or feed additive.

14. A method for inhibiting the proliferation of a bacterium having a menaquinone synthesis pathway via futalosine or a futalosine derivative, the method comprising: a fatty acid having a hydroxyl group at the 10-position and having 18 carbon atoms is administered to a subject.

15. A method for the prevention or treatment of a disease selected from the group consisting of acute gastritis, chronic gastritis, nodular gastritis, gastric ulcer, duodenal ulcer, gastric cancer, gastric MALT lymphoma, diffuse large B-cell lymphoma, idiopathic thrombocytopenic purpura, infantile iron deficiency anemia, chronic urticaria and parkinson's disease, the method comprising: a fatty acid having a hydroxyl group at the 10-position and having 18 carbon atoms is administered to a subject.

16. A method for preventing or treating campylobacter food poisoning or guillain-barre syndrome, the method comprising: a fatty acid having a hydroxyl group at the 10-position and having 18 carbon atoms is administered to a subject.

a fatty acid having a hydroxyl group at the 10-position and having 18 carbon atoms, which is used for the prevention or treatment of a disease selected from the group consisting of acute gastritis, chronic gastritis, nodular gastritis, gastric ulcer, duodenal ulcer, gastric cancer, gastric MALT lymphoma, diffuse large B-cell lymphoma, idiopathic thrombocytopenic purpura, infantile iron deficiency anemia, chronic urticaria and parkinson's disease.

A fatty acid having 18 carbon atoms and having a hydroxyl group at the 18-position, which is used for the prevention or treatment of campylobacter food poisoning or guillain-barre syndrome.

Use of a fatty acid having 18 carbon atoms and having a hydroxyl group at the 10-position for producing a bacterial growth inhibitor having a menaquinone synthesis pathway via futalosine or a futalosine derivative.

Use of a fatty acid having a hydroxyl group at the 20.10-position and having 18 carbon atoms for the production of a prophylactic or therapeutic agent for a disease selected from the group consisting of acute gastritis, chronic gastritis, nodular gastritis, gastric ulcer, duodenal ulcer, gastric cancer, gastric MALT lymphoma, diffuse large B-cell lymphoma, idiopathic thrombocytopenic purpura, infantile iron deficiency anemia, chronic urticaria and parkinson's disease.

Use of a fatty acid having a hydroxyl group at the 21.10-position and having 18 carbon atoms for the production of a prophylactic or therapeutic agent for campylobacter food poisoning or guillain-barre syndrome.

Technical Field

The present invention relates to a composition for inhibiting growth of a bacterium having a menaquinone synthesis pathway via futalosine or a futalosine derivative (preferably, a bacterium belonging to the genus helicobacter (cell: ヘ リ コ バ ク タ ー) or a bacterium belonging to the genus campylobacter (cell: カ ン ピ ロ バ ク タ ー)), the composition containing a fatty acid having a hydroxyl group at the 10-position and having 18 carbon atoms as an active ingredient. The present invention also relates to a composition for preventing or treating a disease caused by a helicobacter bacterium or a composition for preventing or treating a disease caused by a campylobacter bacterium. In addition, the present invention relates to the composition as a food, a pharmaceutical, a feed or the like.

Background

Currently, about 50% of the population carries helicobacter bacteria in the digestive tract. It is known that helicobacter carriers (owners) may not have subjective symptoms of gastritis, gastralgia, or gastric cancer. Since the route of infection by helicobacter is oral and via feces, the infection rate by helicobacter is higher in developing countries with poor hygiene.

In the case of infection with helicobacter pylori (ヘ リ コ バ ク タ ー seed ピ ロ リ), which is one of helicobacter species, the infection was detected by urease TEST (13C-UREA break TEST) and was subjected to sterilization treatment. As a method of sterilization, 3-dose combination therapy of a proton pump inhibitor inhibiting gastric acid secretion and antibiotics (penicillins and macrolides) has been established, but it is said that about 90% of the sterilization rate is achieved and there is a possibility that helicobacter pylori which is not purified may proliferate again. In addition, it has been reported that the sterilization method has side effects such as diarrhea, dysgeusia, allergic reactions, and the occurrence of multidrug-resistant bacteria. The main cause of the side effects is thought to be the change in the intestinal flora caused by the large amount of administration of broad-spectrum antibiotics.

Further, among helicobacter species bacteria infected with human stomach, helicobacter suis (ヘ リ コ バ ク タ ー. cndot.: ス イ ス) is often negative to urease test even when infected, and is difficult to diagnose and a sterilization method has not been established because it is a bacterium having poor culturability. Further, it is known that about 60% of patients with gastric MALT lymphoma, which is one of gastric cancers, have negative results of helicobacter pylori test, but have been infected with bacteria such as helicobacter suis contained in generalized heliothis heilmann (ヘ リ コ バ ク タ ー seed ハ イ ル マ ニ イ セ ン ス ラ ト).

In addition, poultry infected with campylobacter bacteria are a significant cause of food poisoning in humans. In particular, chicken in circulation is said to have a high germ carrying rate. Although bacterial contamination of Campylobacter bacteria may occur in chicken houses or poultry processing plants (bird processing, Japanese highlands), the exact source of contamination has not been clarified yet. Campylobacter infection in humans is mainly manifested by fever or gastroenteritis, and complications include Guillain-Barre syndrome, which is a neurological disorder.

As probiotic bacteria that inhibit the proliferation of helicobacter bacteria, lactobacillus gasseri (ラ ク ト バ チ ル ス seed ガ セ リ) has been reported (patent document 1, non-patent document 1). It is also known that menaquinone (vitamin K2) is an essential component in the electron transport system of bacteria, but it is suggested that helicobacter bacteria and campylobacter bacteria have a menaquinone synthesis pathway via futalosine or a futalosine derivative, which is different from menaquinone synthesis pathways possessed by lactic acid bacteria, escherichia coli, and the like (non-patent document 2). It has been reported that a linear unsaturated fatty acid (patent document 2, non-patent document 3, non-patent document 4) or a branched saturated fatty acid (non-patent document 5) targeting a menaquinone synthesis pathway via futalosine or a futalosine derivative has an effect of inhibiting the proliferation of helicobacter pylori. Furthermore, there has been reported a food and drink (drink, beverage, and food) for removing helicobacter pylori containing a free hydroxy fatty acid as an active ingredient (patent document 3). Further, octanoic acid, which is a medium-chain fatty acid, is known as a compound that inhibits the growth of bacteria of the genus campylobacter (non-patent document 6).

As described above, since the menaquinone synthesis pathway differs depending on the bacteria, only a compound that can more strongly block the menaquinone synthesis pathway possessed by pathogenic microorganisms including helicobacter bacteria or campylobacter bacteria can suppress the proliferation of pathogenic microorganisms without destroying the intestinal flora. Therefore, compounds that can more effectively block the menaquinone synthesis pathway via futalosine or a futalosine derivative are sought.

Disclosure of Invention

Problems to be solved by the invention

The invention aims to: it is found that a compound which inhibits the menaquinone synthesis pathway via futalosine or a futalosine derivative more effectively than a known compound which inhibits the menaquinone synthesis pathway via futalosine or a futalosine derivative, and a composition for inhibiting the proliferation of a bacterium which has the menaquinone synthesis pathway via futalosine or a futalosine derivative and contains the compound as an active ingredient; and a composition for preventing or treating a disease caused by a bacterium having a menaquinone synthesis pathway via futalosine or a futalosine derivative.

Means for solving the problems

the present inventors have conducted intensive studies in view of the above problems, and as a result, have found that: the fatty acid having 18 carbon atoms and a hydroxyl group at the 10-position has previously unknown physiological functions, namely, an inhibitory activity on the proliferation of helicobacter pylori and helicobacter suis, an inhibitory activity on the increase in the number of Ki-67 positive cells, an inhibitory activity on the increase in the expression level of CD19 and the expression level of CD20, and an inhibitory activity on the pathogenesis of gastric MALT lymphoma. In addition, the present inventors have also found that: the fatty acid having 18 carbon atoms and having a hydroxyl group at the 10-position has a growth inhibitory activity against campylobacter jejuni (カ ン ピ ロ バ ク タ ー seed ジ ェ ジ ュ ニ) and campylobacter coli (カ ン ピ ロ バ ク タ ー seed コ リ).

Based on the above findings, the present invention has been completed.

Namely, the present invention is as follows.

[1] A composition for inhibiting the growth of a bacterium having a menaquinone synthesis pathway via futalosine or a futalosine derivative, said composition comprising a fatty acid having a hydroxyl group at the 10-position and having 18 carbon atoms.

[2] [1] the composition according to any one of the preceding claims, wherein the fatty acid has a cis-double bond at least at the 12-position.

[3] [2] the composition according to the above, wherein the fatty acid is at least one selected from the group consisting of 10-hydroxy-cis-12-octadecenoic acid, 10-hydroxy-cis-12, cis-15-octadecadienoic acid and 10-hydroxy-cis-6, cis-12-octadecadienoic acid.

[4] [3] the composition according to (1), wherein the fatty acid is 10-hydroxy-cis-12-octadecenoic acid.

[5] The composition according to any one of [1] to [4], wherein the bacterium is a helicobacter bacterium.

[6] [5] the composition according to any one of the above aspects, wherein the helicobacter is selected from the group consisting of helicobacter pylori and helicobacter suis.

[7] [5] or [6] for the prevention or treatment of a disease selected from the group consisting of acute gastritis, chronic gastritis, nodular gastritis, gastric ulcer, duodenal ulcer, gastric cancer, gastric MALT lymphoma, diffuse large B-cell lymphoma (porthole ま: B cells リ ン パ), idiopathic thrombocytopenic purpura, pediatric iron deficiency anemia, chronic urticaria and Parkinson's disease.

[8] The composition according to any one of [1] to [4], wherein the bacterium is a bacterium belonging to the genus Campylobacter.

[9] [8] the composition, wherein the Campylobacter bacterium is selected from the group consisting of Campylobacter jejuni and Campylobacter coli.

[10] the composition of [8] or [9], which is used for the prevention or treatment of campylobacter food poisoning or Guillain-Barre syndrome.

[11] The composition according to any one of [1] to [10], which is a food or a food additive.

[12] The composition according to any one of [1] to [10], which is a pharmaceutical product.

[13] The composition according to any one of [1] to [10], which is a feed or a feed additive.

[14] A method for inhibiting the proliferation of a bacterium having a menaquinone synthesis pathway via futalosine or a futalosine derivative, the method comprising: a fatty acid having a hydroxyl group at the 10-position and having 18 carbon atoms is administered to a subject.

[15] a method for the prevention or treatment of a disease selected from the group consisting of acute gastritis, chronic gastritis, nodular gastritis, gastric ulcer, duodenal ulcer, gastric cancer, gastric MALT lymphoma, diffuse large B-cell lymphoma, idiopathic thrombocytopenic purpura, infantile iron deficiency anemia, chronic urticaria and parkinson's disease, the method comprising: a fatty acid having a hydroxyl group at the 10-position and having 18 carbon atoms is administered to a subject.

[16] A method for preventing or treating campylobacter food poisoning or guillain-barre syndrome, the method comprising: a fatty acid having a hydroxyl group at the 10-position and having 18 carbon atoms is administered to a subject.

[17] A fatty acid having a hydroxyl group at the 10-position and having 18 carbon atoms, which is used for the prevention or treatment of a disease selected from the group consisting of acute gastritis, chronic gastritis, nodular gastritis, gastric ulcer, duodenal ulcer, gastric cancer, gastric MALT lymphoma, diffuse large B-cell lymphoma, idiopathic thrombocytopenic purpura, infantile iron deficiency anemia, chronic urticaria and parkinson's disease.

[18] A fatty acid having a hydroxyl group at the 10-position and having 18 carbon atoms, which is used for the prevention or treatment of campylobacter food poisoning or guillain-barre syndrome.

[19] Use of a fatty acid having 18 carbon atoms and having a hydroxyl group at the 10-position for the production of a bacterial growth inhibitor having a menaquinone synthesis pathway via futalosine or a futalosine derivative.

[20] Use of a fatty acid having a carbon number of 18 and a hydroxyl group at position 10 for the production of a prophylactic or therapeutic agent for a disease selected from the group consisting of acute gastritis, chronic gastritis, nodular gastritis, gastric ulcer, duodenal ulcer, gastric cancer, gastric MALT lymphoma, diffuse large B-cell lymphoma, idiopathic thrombocytopenic purpura, infantile iron deficiency anemia, chronic urticaria and parkinson's disease.

[21] Use of a fatty acid having a hydroxyl group at the 10-position and having 18 carbon atoms for the manufacture of a prophylactic or therapeutic agent for campylobacter food poisoning or guillain-barre syndrome.

Effects of the invention

The present invention provides: a composition for inhibiting the growth of a bacterium having a menaquinone synthesis pathway via futalosine or a futalosine derivative, the composition containing a fatty acid having a hydroxyl group at the 10-position and having 18 carbon atoms as an active ingredient; and a composition for preventing or treating a disease caused by a bacterium having a menaquinone synthesis pathway via futalosine or a futalosine derivative. The composition can be used in various fields such as medicines, foods, feeds, and the like, and therefore the present invention is also very useful industrially.

Drawings

[ FIG. 1-1] shows the proliferation inhibitory effect of HYA on H.pylori SS1 strain (in vitro).

[ FIGS. 1-2] show the proliferation inhibitory effect of HYA on H.pylori TN2GF4 strain (in vitro).

[ FIGS. 1-3] show the proliferation inhibitory effect of HYA on H.pylori ATCC43579 strain (in vitro).

[ FIGS. 1-4] show the proliferation-inhibiting effect of HYA on the H.pylori NCTC11637 strain (in vitro).

[ FIGS. 1-5] show the proliferation-inhibiting effect of HYA on H.pylori TY281 strain (in vitro).

[ FIGS. 1-6] show the proliferation-inhibiting effect of HYA on H.pylori TY1345 strain (in vitro).

[ FIG. 2-1] shows the proliferation inhibitory effect of low concentration HYA on H.pylori SS1 strain (in vitro).

[ FIG. 2-2] shows the proliferation inhibitory effect of low concentrations of HYA on H.pylori TN2GF4 strain (in vitro).

[ FIGS. 2-3] show the proliferation-inhibiting effect of low concentrations of HYA on H.pylori TK1029 strain (in vitro).

[ FIGS. 2-4] show the proliferation-inhibiting effect of low concentrations of HYA on the strain of helicobacter pylori RC-1 (in vitro).

[ FIG. 3-1] shows the proliferation inhibitory effect (in vivo) of fatty acid against helicobacter pylori SS1 strain.

[ FIGS. 3-2] show the growth inhibitory effect (in vivo) of fatty acids on the strain helicobacter pylori TN2GF 4.

[ FIG. 4-1] shows the proliferation inhibitory effect of HYA on H.pylori SS1 strain (in vivo).

[ FIG. 4-2] shows the proliferation inhibitory effect of HYA on H.pylori TN2GF4 strain (in vivo).

[ FIGS. 4-3] show the proliferation inhibitory effect of HYA on the helicobacter suis TKY strain or SNTW101 strain (in vivo).

[ FIG. 5-1] shows the proliferation inhibitory effect of HYA on the helicobacter suis TKY strain (in vivo).

[ FIG. 5-2] shows the inhibitory effect of HYA on the increase in the number of Ki-67-positive cells in stomach tissue of mice infected with the helicobacter suis TKY strain (in vivo).

[ FIGS. 5-3] show the inhibitory effect of HYA on the increase in expression of CD20 in stomach tissue of mice infected with the helicobacter suis TKY strain (in vivo).

[ FIGS. 5-4] show the inhibitory effect of HYA on the increase in expression of CD19 in stomach tissue of mice infected with the helicobacter suis TKY strain (in vivo).

[ FIG. 6-1] shows the proliferation inhibitory effect of HYA on Campylobacter jejuni ATCC33560 strain (in vitro).

[ FIG. 6-2] shows the proliferation inhibitory effect of HYA on Campylobacter coli ATCC33559 strain (in vitro).

[ FIGS. 6-3] show the proliferation inhibitory effect of HYA on Campylobacter jejuni ATCC33560 strain (in vitro).

[ FIGS. 6-4] show the proliferation inhibitory effect of HYA on Campylobacter coli ATCC33559 strain (in vitro).

Detailed Description

the present invention provides: a composition for inhibiting the growth of a bacterium having a menaquinone synthesis pathway via futalosine or a futalosine derivative (hereinafter, also referred to as the composition of the present invention) which contains a fatty acid having a hydroxyl group at the 10-position and having 18 carbon atoms.

The composition of the present invention contains a fatty acid having 18 carbon atoms and having a hydroxyl group at the 10-position (hereinafter also referred to as a hydroxylated fatty acid of the present invention). The hydroxylated fatty acid of the present invention may be a saturated fatty acid or an unsaturated fatty acid. In the case of an unsaturated fatty acid, an unsaturated fatty acid having at least one double bond selected from a cis double bond at position 6, a cis double bond at position 12, a cis double bond at position 15 and a trans double bond at position 11 is preferred, and an unsaturated fatty acid having a cis double bond at least at position 12 is more preferred.

More specifically, the hydroxylated fatty acids of the present invention include: 10-hydroxy-cis-12-octadecenoic acid (hereinafter also referred to as HYA), 10-hydroxy-cis-12, cis-15-octadecadienoic acid (hereinafter also referred to as. alpha. HYA), 10-hydroxy-cis-6, cis-12-octadecadienoic acid (hereinafter also referred to as. gamma. HYA), 10-hydroxy-cis-6, cis-12, cis-15-octadecatrienoic acid (hereinafter also referred to as sHYA), 10, 12-dihydroxyoctadecanoic acid (hereinafter also referred to as. rHYA), 10-hydroxy-trans-11-octadecenoic acid (hereinafter also referred to as HYC), 10-hydroxy-trans-11, cis-15-octadecadienoic acid (hereinafter also referred to as. alpha. HYC), 10-hydroxy-cis-6, trans-11-octadecadienoic acid (hereinafter also referred to as γ HYC), 10-hydroxy-cis-6, trans-11, cis-15-octadecatrienoic acid (hereinafter also referred to as sHYC), and the like, and 10-hydroxy-cis-12-octadecadienoic acid, 10-hydroxy-cis-12, cis-15-octadecadienoic acid, 10-hydroxy-cis-6, cis-12-octadecadienoic acid are preferably listed, and 10-hydroxy-cis-12-octadecadienoic acid is more preferably listed.

The hydroxylated fatty acid of the invention can be prepared by known methods, and for example, a production method is also described in WO 2013/168310. Further, 10-hydroxy-cis-12-octadecenoic acid can be prepared by reference to Biochemical and biophysical research Communications 416(2011) pp.188-193 and the like.

The hydroxylated fatty acid of the present invention has a growth inhibitory effect on a bacterium having a menaquinone synthesis pathway via futalosine or a futalosine derivative (hereinafter, also referred to as a futalosine-synthesizing bacterium). In the present invention, the futalosine-synthesizing bacterium refers to a bacterium having, among metabolic pathways for synthesizing menaquinone, a metabolic pathway for synthesizing menaquinone from chorismic acid via futalosine or a futalosine derivative (hereinafter also referred to as futalosine pathway). Here, examples of the futalosine derivative include: aminodeoxy futalones, nor-hypoxanthine futalones, cyclic nor-hypoxanthine futalones and 1, 4-dihydroxy-6-naphthoic acid. In the futalosine pathway, futalosine is synthesized from chorismic acid and inosine. In addition, aminodeoxyfutalosine is synthesized from chorismate and adenosine. Subsequently, futanoine or aminodeoxy futanoine is metabolized into hypoxanthine futanoine, hypoxanthine futanoine is metabolized into cyclic hypoxanthine futanoine, cyclic hypoxanthine futanoine is metabolized into 1, 4-dihydroxy-6-naphthoic acid, and finally 1, 4-dihydroxy-6-naphthoic acid is metabolized into menaquinone.

Menaquinone is an essential component in the electron transport system of bacteria, and two pathways are known as synthetic pathways in bacteria. One is a pathway for synthesizing menaquinone from chorismic acid via succinylbenzoic acid (hereinafter also referred to as succinylbenzoic acid pathway), and is mainly provided in escherichia coli, lactic acid bacteria, bifidobacterium, enterococcus, salmonella, shigella, listeria, yersinia, bacillus subtilis, and the like. The other is the futalosine pathway clarified by genetic analysis in recent years. As a bacterium having both succinylbenzoic acid pathway and futalosine pathway, Stackebrandtia nasauensis DSM 44728, which is one of actinomycetes, has been known, and a bacterium having a metabolic pathway for biosynthesis of menaquinone other than this bacterium has only one of the pathways. Therefore, the hydroxylated fatty acid of the invention that can block the futalosine pathway can specifically inhibit the proliferation of futalosine-synthesizing bacteria. In the present invention, the futalosine-synthesizing bacterium is not particularly limited as long as it has a futalosine pathway, and a bacterium not having a succinylbenzoic acid pathway is preferable. Examples of the futalosine-synthesizing bacteria include: helicobacter, campylobacter, chlamydia (ク ラ ミ デ ィ ア), thermus (サ ー マ ス), inolin (ウ ォ リ ネ ラ), streptomyces (ス ト レ プ ト マ イ セ ス), thermoacidoid (ア シ ド サ ー マ ス), northern sporotrichum (キ タ サ ト ス ポ ラ), and bacillus (バ シ ラ ス). In the present invention, examples of helicobacter include: helicobacter pylori, helicobacter pylori in the broad sense (including helicobacter suis, helicobacter felis, helicobacter salmon, helicobacter pili, helicobacter corynebacterium, helicobacter canis, helicobacter pylori in the narrow sense), helicobacter geesteranus, helicobacter pantherini, helicobacter bile, helicobacter geese, helicobacter canadian, helicobacter canis, helicobacter cholecyst, helicobacter homophilic, helicobacter hepaticus, helicobacter microti, helicobacter pomi, helicobacter rodent, helicobacter frequentis, etc., preferably helicobacter pylori and helicobacter suis. In the present invention, examples of bacteria of the genus campylobacter include: campylobacter coli, Campylobacter concubilis, Campylobacter fetus, Campylobacter jejuni, Campylobacter salivarius, Campylobacter mucosae, Campylobacter rectum, etc., preferably Campylobacter jejuni and Campylobacter coli. In the present invention, examples of the bacterium belonging to the genus chlamydia include: chlamydia murinus, chlamydia suis, chlamydia trachomatis, and the like. In the present invention, examples of the Thermus bacteria include: thermus anserina, Thermus aquaticus, Thermus thermobifidus, Thermus thermophilus, etc. In the present invention, as the bacteria of the genus Wolinella, there can be mentioned: wolinella curvatica, Wolinella succinogenes, Wolinella recta, etc. In the present invention, examples of the Streptomyces bacteria include: streptomyces avermitilis, streptomyces coelicolor, streptomyces scabies, streptomyces lividans and the like. In the present invention, examples of the thermoacidobacter bacteria include: acidothermus cellulolyticus, and the like. In the present invention, examples of the bacterium belonging to the genus northern sporotrichum include: northern sporotrichum brevicaulis, etc. In the present invention, examples of the bacterium belonging to the genus Bacillus include: bacillus cereus, Bacillus subtilis, Bacillus thuringiensis, etc.

In addition, since the hydroxylated fatty acid of the present invention can inhibit the proliferation of a futalosine-synthesizing bacterium, the present invention can be used for the prevention or treatment of a disease in the case where the futalosine-synthesizing bacterium is a bacterium that causes the disease by infecting a human or an animal other than a human (hereinafter, also referred to as a pathogenic futalosine-synthesizing bacterium). Examples of pathogenic fumalogine-synthesizing bacteria include: helicobacter bacteria, Campylobacter bacteria, Chlamydia bacteria, Wolinella bacteria, Bacillus bacteria, etc. In the case where the pathogenic futalosine-synthesizing bacterium is a helicobacter bacterium, examples of the disease that can be prevented or treated by the composition of the present invention include: gastric diseases such as acute gastritis, chronic gastritis, nodular gastritis, gastric ulcer, duodenal ulcer, gastric cancer, and gastric MALT lymphoma; or an extragastric disease such as diffuse large B-cell lymphoma, idiopathic thrombocytopenic purpura, infantile iron-deficiency anemia, chronic urticaria, or the like, or a parkinson's disease, and preferably includes gastric diseases such as acute gastritis, chronic gastritis, nodular gastritis, gastric ulcer, duodenal ulcer, gastric cancer, and gastric MALT lymphoma. In the case where the pathogenic futalosine-synthesizing bacterium is a bacterium of the genus campylobacter, examples of the disease that can be prevented or treated by the composition of the present invention include: campylobacter food poisoning, guillain-barre syndrome, and the like. In the case where the pathogenic futalosine-synthesizing bacterium is a bacterium of the genus chlamydia, examples of the disease that can be prevented or treated by the composition of the present invention include: chlamydial infections, trachoma, pneumonia, psittacosis, etc. When the pathogenic futalosine-synthesizing bacterium is a bacterium belonging to the genus Wolinella, periodontitis and the like can be mentioned as diseases that can be prevented or treated by the composition of the present invention. In the case where the pathogenic futalosine-synthesizing bacterium is a bacterium of the genus bacillus, examples of the disease that can be prevented or treated by the composition of the present invention include: food poisoning, bacteremia, pneumonia, endocarditis, eye infection, opportunistic infection, etc.

The composition of the present invention can be used as, or incorporated into, for example, a pharmaceutical product, a food product, a feed, or the like.

When the composition of the present invention is used as a pharmaceutical product, the dosage form of the pharmaceutical product may be: powder, granule, pill, soft capsule, hard capsule, tablet, chewable tablet, disintegrating tablet, syrup, solution, suspension, suppository, ointment, cream, gel, patch (adhesive), inhalant, injection, etc. These preparations can be prepared by a conventional method.

Examples of additives that can be used for the preparation of the formulation include: animal and plant oils such as soybean oil, safflower oil, olive oil, germ oil, sunflower oil, beef tallow, sardine oil, etc.; polyhydric alcohols such as polyethylene glycol, propylene glycol, glycerin, and sorbitol; surfactants such as sorbitan fatty acid esters, sucrose fatty acid esters, glycerin fatty acid esters, and polyglycerin fatty acid esters; purified water; excipients such as lactose, starch, crystalline cellulose, D-mannitol, lecithin, acacia, sorbitol solution, and sugar solution; sweeteners, colorants, pH adjusters, flavorants, and the like. It is noted that the liquid preparation may be in the form of a solution or suspension in water or other suitable medium at the time of administration. In addition, tablets and granules can be coated by a known method.

In the case of administration in the form of an injection, administration into the vein, the abdominal cavity, the muscle, the subcutaneous, the transdermal, the intra-articular, the synovial capsule (synovial capsule), the intracellular membrane, the intraosseous membrane, the sublingual, the oral cavity, and the like is preferable, and particularly, intravenous administration or intraperitoneal administration is preferable. The intravenous administration may be either drip administration or bolus administration.

When the composition of the present invention is used as a food or food additive, the food is not particularly limited as long as it is in a form that can be orally ingested, such as a solution, a suspension, a powder, a solid molded product, or the like. As specific examples, there may be mentioned: supplements (powder, granule, soft capsule, hard capsule, tablet, chewable tablet, rapidly disintegrating tablet, syrup, solution, etc.), beverages (carbonated beverage, lactic acid beverage, sports beverage, fruit juice beverage, vegetable beverage, soy milk beverage, coffee beverage, tea beverage, powdered beverage, concentrated beverage, nutritional beverage, alcoholic beverage, etc.), desserts (soft candy, jelly, chewing gum, chocolate, cookie, candy, caramel, Japanese snack, etc.), instant foods (instant noodles, steamed food, canned food, microwave food, instant soup/miso juice, freeze-dried food, etc.), oils, fatty foods (mayonnaise, dressing, butter, cream, margarine, etc.), wheat flour products (bread, pasta, noodles, cake mix, bread powder, etc.), seasonings (sauce, tomato processing seasoning, flavor seasoning, etc.) Cooking mixes, soups, etc.), processed animal products (meat ham, sausage, etc.).

The food may be blended with various nutrients, vitamins (vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin C, vitamin D, vitamin E, vitamin K, etc.), minerals (magnesium, zinc, iron, sodium, potassium, selenium, etc.), dietary fiber, stabilizer such as dispersant, emulsifier, etc., sweetener, flavoring component (citric acid, malic acid, etc.), essence, royal jelly, propolis, agaricus tabularis, etc., as required.

In the case where the composition of the present invention is used as a feed or a feed additive, the feed may include: pet food, livestock or aquaculture feed additives, and the like.

As subjects to administer or ingest the composition of the present invention, there can be mentioned: a human or non-human animal (e.g., dog, cat, mouse, rat, hamster, guinea pig, rabbit, pig, cow, chicken, parrot, hill myna, goat, horse, sheep, monkey, etc.).

The amount of administration or intake of the composition of the present invention varies depending on the subject of administration or intake, the subject disease, symptoms, route of administration or intake, etc., and for example, the fatty acid contained in the composition of the present invention may be generally administered orally (orally) or parenterally in an amount of 0.02 to 100mg/kg body weight, preferably 0.2 to 50 mg/kg body weight, more preferably 0.5 to 20 mg/kg body weight, as an administration or intake for 1 day. Administration or ingestion may be divided into several times in 1 day. In addition, the amount may be increased or decreased depending on the symptoms.

The present invention will be described more specifically with reference to the following examples, which are merely illustrative of the present invention and do not limit the scope of the present invention.